Vitrolife AB is primarily active in the field of life sciences and reproductive medicine. As a leading biotechnology company, Vitrolife specializes in providing innovative solutions for fertility treatment and research. With its range of products and services, Vitrolife supports assisted reproductive technology (ART) procedures such as in vitro fertilization (IVF) and preimplantation genetic testing (PGT). The company's expertise and dedication to advancing reproductive medicine have made Vitrolife a trusted partner for clinics, researchers, and patients worldwide.

The main competitors of Vitrolife AB in the market include other leading companies in the field of assisted reproductive technology, such as Cook Medical Inc., Irvine Scientific, and Origio A/S. These companies offer similar products and services, aiming to provide innovative solutions for fertility treatments. However, Vitrolife AB sets itself apart through its extensive product portfolio, strategic partnerships, and continuous investment in research and development. With its strong presence in the market, Vitrolife AB maintains a competitive edge and remains a trusted choice for healthcare professionals and patients seeking high-quality solutions in assisted reproduction.

Vitrolife AB is a leading global biotechnology company that specializes in developing, manufacturing, and marketing products for assisted reproduction. Established in 1994, Vitrolife has a rich history and a strong background in the field of reproductive medicine. The company's mission is to increase the success rates of in vitro fertilization (IVF) by offering innovative solutions and high-quality products to fertility clinics worldwide. With a dedicated team of experts and continuous research and development efforts, Vitrolife strives to improve the chances of pregnancy and ultimately contribute to the happiness of families around the globe.

Vitrolife AB, a leading biotechnology company, has achieved several significant milestones. Over the years, the company has made groundbreaking innovations in the field of assisted reproduction, helping countless individuals achieve their desire of starting a family. Vitrolife AB developed cutting-edge products and techniques like time-lapse incubation systems and sequential media, revolutionizing the success rates of in vitro fertilization (IVF) procedures. The company has also expanded its global presence, establishing a strong presence in key markets worldwide. As a result, Vitrolife AB continues to be recognized as an industry leader, driving advancements in assisted reproductive technology and providing hope for couples struggling with infertility.

Vitrolife AB is primarily present in several countries and regions worldwide. These include Europe, North America, Asia, and Australia. The company has established a strong presence in Europe, with operations and distribution networks in countries such as Sweden, Germany, France, and the United Kingdom. In North America, Vitrolife AB has a significant presence in the United States and Canada. The company also operates in various countries across Asia, including China, Japan, and India. Additionally, Vitrolife AB has expanded into the Australian market, further enhancing its global presence.

Vitrolife AB represents a strong commitment to driving innovation and advancing the field of assisted reproduction. The company's values revolve around ensuring patient safety and providing high-quality products and expertise. With a corporate philosophy focused on continuous improvement, Vitrolife AB strives to offer cutting-edge solutions that improve outcomes and enhance the chances of successful pregnancies. Through their comprehensive product portfolio, integrated workflow systems, and ongoing dedication to research and development, Vitrolife AB remains at the forefront of reproductive technology, empowering fertility clinics worldwide to achieve their goals and help individuals and couples achieve their dream of having a baby.

Analysts currently set an average price target of 163.20 SEK for the Vitrolife stock (median: 163.20 SEK), implying +84.6 % versus the latest price. The consensus is based on 10 analyst ratings.

Vitrolife Analyst Price Targets 2026

10 analysts currently rate the Vitrolife stock: 8 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Vitrolife to generate revenue of 3.45 B SEK and earnings per share of 4.11 SEK.

Vitrolife Analyst Price Targets 2026

Converted at the current exchange rate, the Vitrolife share trades at 8.01 EUR (88.40 SEK).

The Vitrolife share (VITR.ST) is listed on 6 stock exchanges, including: Frankfurt (VTFN.F), München (VTFN.MU), Düsseldorf (VTFN.DU), London (0YAY.L).

Vitrolife AB is a leading provider of products and services for reproductive medicine. The company operates in three business areas, each specializing in in vitro fertilization, stem cells, and tissue transplantation. In the field of in vitro fertilization (IVF), Vitrolife offers a wide range of products and services tailored to the needs of fertility clinics and research institutions. These include soluble culture media that optimize the in vitro development of eggs, sperm, and embryos. The company also offers products for the cryopreservation of eggs and embryos, as well as devices for the accurate application of IVF technology. In the field of stem cells, Vitrolife offers specialized culture media and other products that optimize the production and treatment of stem cells. The company is a leader in the development and provision of high-quality culture media for stem cells, and has also developed a wide range of accessories and devices to support stem cell experiments and procedures. In the field of tissue transplantation, Vitrolife offers artificial body fluids and surgical transplantation products for various applications. The area also includes products for the expansion of tissue cultures and various molecular kits that have been specifically developed to provide greater benefit in tissue transplantation. Vitrolife's business model is based on a combination of research and development, production, distribution, and marketing of products and services tailored to the needs of research institutions and medical centers. The company operates in a global market, with the US being the largest individual market. Thanks to a strong local presence and a prominent international focus, Vitrolife can serve both small and large markets in all geographic regions, taking into account the specifics of each region through continuous development. Customers can rely on a high standard of quality, innovative and forward-thinking products, and effective, precise solutions that Vitrolife customizes and delivers to its customers. The company has an excellent reputation in the industry and is known for having a dedicated research and development department. Vitrolife continuously works on improving its products and services to provide the highest quality. Overall, Vitrolife is a stable, innovative company with a mature business model. The company is well-positioned to continue growing and strive for global market leadership in a rapidly expanding market with promising future prospects.

The expected revenue of Vitrolife is 3.45 B SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Vitrolife is 555.91 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Vitrolife is currently 21.53. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vitrolife stock.

The price-to-sales ratio (P/S) of Vitrolife is currently 3.47. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vitrolife stock.

The Eulerpool Quality Score for Vitrolife is 3/10.

The ISIN of Vitrolife is SE0011205202. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Vitrolife is A2JLT3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Vitrolife is VITR.ST. The ticker symbol is used to trade Vitrolife shares on the stock exchange.

Over the past 12 months, Vitrolife paid a dividend of 1.10 SEK . This corresponds to a dividend yield of about 1.24 %. For the coming 12 months, Vitrolife is expected to pay a dividend of 1.17 SEK.

The current dividend yield of Vitrolife is 1.24 %.

Vitrolife pays a dividend, distributed in the months of , , , .

Vitrolife paid dividends every year for the past 5 years.

For the upcoming 12 months, dividends amounting to 1.17 SEK are expected. This corresponds to a dividend yield of 1.33 %.

Vitrolife is assigned to the 'Health' sector.

To receive the latest dividend of Vitrolife from amounting to 1.1 SEK, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Vitrolife distributed 2 SEK as dividends.

The dividends of Vitrolife are distributed in SEK.